The present study investigated the contribution of microsomal cytochrome P450 and cytosolic aldehyde oxidase-1 (AOX-1) to carbazeran 4-oxidation and O 6-benzylguanine 8-oxidation in human liver microsomal, cytosolic, and S9 fractions. Incubations containing carbazeran and human liver microsomes with or without exogenously added NADPH yielded comparable levels of 4-oxo-carbazeran. O 6-Benzylguanine 8-oxidation occurred in microsomal incubations, and the extent was increased by NADPH. Human recombinant CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 did not catalyze carbazeran 4-oxidation, whereas CYP1A2 was highly active in O 6-benzylguanine 8-oxidation. 1-Aminobenzotriazole, a pancytochrome P450 inhibitor, decreased O 6-benzylguanine 8-oxidation, but not carbazeran 4-oxidation, in microsomal incubations, whereas 1-aminobenzotriazole and furafylline (a CYP1A2-selective inhibitor) did not inhibit carbazeran 4-oxidation or O 6-benzylguanine 8-oxidation in human liver S9 fraction. Carbazeran 4-oxidation in incubations containing human liver microsomes (from multiple donors and commercial suppliers) was attributed to microsomal preparations contaminated with AOX-1, as suggested by liver microsomal experiments indicating a decrease in carbazeran 4-oxidation by an AOX-1 inhibitor (hydralazine), and to detection of AOX-1 protein (at one-third the level of that in liver cytosol). Cytosolic contamination of liver microsomes was further demonstrated by the formation of dehydroepiandrosterone sulfate (catalyzed by cytosolic sulfotransferases) in liver microsomal incubations containing dehydroepiandrosterone. In conclusion, carbazeran 4-oxidation and O 6-benzylguanine 8-oxidation are enzyme-selective catalytic markers of human AOX-1, as shown in human liver S9 fraction expressing cytochrome P450 and AOX-1. This study highlights the negative impact of cytosolic contamination of liver microsomes on the interpretation of reaction phenotyping data collected in an in vitro study performed in microsomal fractions.
Gefitinib and erlotinib are epidermal growth factor receptortyrosine kinase inhibitors (EGFR-TKIs) with activity against metastatic non-small cell lung cancer. Aldehyde oxidase-1 (AOX1) is a cytosolic drug-metabolizing enzyme. We conducted an experimental and molecular docking study on the effect of gefitinib, erlotinib, and select metabolites on the in vitro catalytic activity of AOX1, as assessed by carbazeran 4-oxidation, and determined the impact of AOX1 inhibition on hepatic metabolism of zaleplon and methotrexate. Gefitinib, desmorpholinopropylgefitinib, erlotinib, desmethylerlotinib, and didesmethylerlotinib inhibited human hepatic cytosolic carbazeran 4-oxidation by a competitive mode, with inhibition constants in submicromolar or low micromolar concentrations. Desmethylgefitinib did not affect AOX1 catalytic activity. A similar pattern was obtained when investigated with human kidney cytosol or recombinant AOX1. The differential effect of gefitinib on human, rat, and mouse hepatic AOX1 catalytic activity suggests speciesdependent chemical inhibition of AOX1. Erlotinib was considerably more potent than gefitinib in decreasing hepatic cytosolic zaleplon 5-oxidation and methotrexate 7-oxidation. Molecular docking analyses provided structural insights into the interaction between EGFR-TKIs and AOX1, with key residues and bonds identified, which provided favorable comparison and ranking of potential inhibitors. Based on the US Food and Drug Administration guidance to assess the risk of drug-drug interactions, the calculated R 1 values indicate that further investigations are warranted to determine whether gefitinib and erlotinib impact AOX1-mediated drug metabolism in vivo. Overall, erlotinib desmethylerlotinib, didesmethylerlotinib, gefitinib, and desmorpholinopropylgefitinib are potent inhibitors of human AOX1 catalytic function and hepatic metabolism of zaleplon and methotrexate, potentially affecting drug efficacy or toxicity. SIGNIFICANCE STATEMENTAs epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib are first-line pharmacotherapy for metastatic non-small cell lung cancer. Our experimental findings indicate that clinically relevant concentrations of gefitinib, desmorpholinopropylgefitinib, erlotinib, desmethylerlotinib, and didesmethylerlotinib, but not desmethylgefitinib, inhibit human aldehyde oxidase (AOX1) catalytic activity and hepatic cytosolic metabolism of zaleplon and methotrexate. Molecular docking analysis provide structural insights into the key AOX1 interactions with these EGFR-TKIs. Our findings may trigger improved strategies for new EGFR-TKI design and development.
Aldehyde oxidase‐1 (AOX‐1) is a cytosolic xenobiotic‐metabolizing enzyme that has gained increasing interest because of its emerging role in drug metabolism and toxicity. It is a catalyst of carbazeran 4‐oxidation, resulting in the formation of 4‐oxo‐carbazeran. However, cytochrome P450 is also a catalyst of oxidative reactions. Therefore, we tested the hypothesis that cytochrome P450 and AOX‐1 catalyze carbazeran 4‐oxidation in the endoplasmic reticulum and cytosol, respectively. Incubations containing human liver microsomes with or without NADPH yielded 4‐oxo‐carbazeran, but to a lesser extent than that in incubations containing human liver cytosol. Cytochrome P450 inhibitors (1‐aminobenzotriazole and ketoconazole) did not decrease the extent of carbazeran 4‐oxidation in liver microsomes, whereas an AOX‐1 inhibitor (hydralazine) decreased it in liver cytosol. Human recombinant CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 did not catalyze carbazeran 4‐oxidation, in contrast to the catalysis by recombinant AOX‐1. The extent of carbazeran 4‐oxidation in incubations containing liver microsomes was attributed to the presence of AOX‐1 in the microsomal preparations, as indicated by the decrease in carbazeran 4‐oxidation by an AOX‐1 inhibitor (hydralazine) and the detection of AOX‐1 protein in liver microsomes (at a level that was up to one‐third of that in liver cytosol). Cytosolic sulfotransferases‐catalyzed dehydroepiandrosterone sulfation increased with increasing amount of microsomes, indicating that the two lots of hepatic microsomes are contaminated with not only AOX‐1, but also other cytosolic enzymes. An isomer of 4‐oxo‐carbazeran, putatively identified as 5‐hydroxy‐carbazeran or 8‐hydroxy‐carbazeran, was detected in incubations containing carbazeran and CYP1A2, CYP2D6, CYP3A4, or CYP3A5. The 5‐hydroxy‐carbazeran or 8‐hydroxy‐carbazeran peak was detected in human liver microsomal incubation and the peak area increased with increasing incubation time. The 5‐hydroxy‐carbazeran or 8‐hydroxy‐carbazeran peak was decreased by a pan‐CYP inhibitor (1‐aminobenzotriazole), but not by an AOX‐1 inhibitor (hydralazine). The addition of 1‐aminobenzotriazole increased the 4‐oxo‐carbazeran formation, indicating a shunting of carbazeran metabolism to AOX‐1 in the presence of the CYP inhibitor. In conclusion, carbazeran is a dual substrate of AOX‐1 and cytochrome P450. However, AOX‐1, but not cytochrome P450, catalyzes carbazeran 4‐oxidation.Support or Funding InformationSingapore Ministry of Education Academic Research Fund Tier 1 [Grant R‐148‐000‐218‐112 to AJL]This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.